Ser250
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser250  -  FOXO1A (rat)

Site Information
sPRRRAAsMDNNSkF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448075

In vivo Characterization
Methods used to characterize site in vivo:
phospho-antibody ( 1 , 2 , 3 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
liver cancer ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 3 ) , granulosa ( 2 ) , H4IIe (hepatic) ( 3 ) , muscle ( 1 )

Upstream Regulation
Kinases, in vitro:
Akt1 (rat) ( 3 )
Treatments:
clenbuterol ( 1 ) , D4476 ( 3 ) , dexamethasone ( 1 ) , insulin ( 3 ) , PKI-(14-22)amide ( 2 ) , rapamycin ( 2 ) , TGF-beta ( 2 ) , urofollitropin ( 2 ) , wortmannin ( 2 )

References 

1

Umeki D, et al. (2015) Protective Effects of Clenbuterol against Dexamethasone-Induced Masseter Muscle Atrophy and Myosin Heavy Chain Transition. PLoS One 10, e0128263
26053620   Curated Info

2

Chen YJ, et al. (2007) Interplay of PI3K and cAMP/PKA signaling, and rapamycin-hypersensitivity in TGFbeta1 enhancement of FSH-stimulated steroidogenesis in rat ovarian granulosa cells. J Endocrinol 192, 405-19
17283241   Curated Info

3

Rena G, Bain J, Elliott M, Cohen P (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 5, 60-5
14710188   Curated Info